Chemomab Therapeutics Ltd reports results for the quarter ended in September - Earnings Summary

Chemomab Therapeutics

11/11/2022 12:00

* Chemomab Therapeutics Ltd  CMMB.OQ  reported a quarterly
adjusted loss of 4 cents​​ per share for the quarter ended in
September. The mean expectation of two analysts for the quarter
was for a loss of 33 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Chemomab Therapeutics Ltd's reported EPS for the quarter
was a
loss of 4 cents​.
    * The mean earnings estimate of analysts had fallen by
about 20%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Chemomab Therapeutics Ltd shares had fallen by 16.5% this
quarter and lost 69.9% so far this year.
    * The company reported a quarterly loss of $8.08 million.
    * Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is $21.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
11 at 11:59 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.33          -0.03          Beat
 Jun. 30 2022      -0.25          -0.54          Missed
 Mar. 31 2022      -0.24          -0.44          Missed
 Dec. 31 2021      -0.10          -0.44          Missed